A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

NCT03879122 | Unknown Phase 2

• 1 other identifier: CA209-9HX
• Study Type: interventional
• Target: 135
• Locations: 1 country
• Sites: 30

Brief Summary

Metastatic prostate cancer is an incurable disease that typically spreads beyond the prostate. The standard of care is to systemically treat the disease with androgen deprivation therapy (ADT). However, the disease progresses in virtually all patients to the state of castration resistant prostate cancer (CRPC), with a median time to progression of 24 months. Patients with high volume disease (with either visceral metastasis and/or bone metastasis) exhibit a worse prognosis, with a median clinical progression of 14 months. Recently, the CHAARTED and STAMPEDE studies demonstrated that the combination of Docetaxel (chemotherapy) and ADT delayed the clinical progression and improved the survival a median of 14 months (17 for high volume patients). Nevertheless, the prognosis of patients with high volume metastatic disease continues to be poor. Meanwhile the immunotherapy, the use of antibodies that recognize tumoral cells and promote the immune system activity against the cancer, has emerged as a very useful option in many cancers. Among others, the antibodies Nivolumab and Ipilimumab have been approved for the treatment of multiple types of cancer. In this context, SOGUG (Spanish Oncology Genitourinary Group) has designed this new study "PROSTRATEGY" with the objective of evaluating whether the addition of immunotherapy to chemotherapy and ADT improves the prognosis and survival of patients with high volume metastatic hormone-sensitive prostate cancer.

Conditions

Metastatic Hormone-sensitive Prostate Cancer

Keywords

prostate cancer; immunotherapy

Outcome Measures

Primary Outcomes (1)

• Overall Survival

  Overall Survival

  through study completion, an average of 2 years

Secondary Outcomes (13)

• PSA response

  through study completion, an average of 2 years

• PSA progression-free survival (PSA-PFS)

  through study completion, an average of 2 years

• Radiological progression-free survival (rPFS)

  through study completion, an average of 2 years

• Clinical progression-free survival (cPFS)

  through study completion, an average of 2 years

• Time to castration resistant prostate cancer (TCRPC)

  through study completion, an average of 2 years

Study Arms (3)

ADT + Docetaxel

ACTIVE COMPARATOR

ADT (androgen deprivation therapy) plus 6 cycles of DOCETAXEL

Drug: Docetaxel; Drug: ADT (androgen deprivation therapy)

ADT + Docetaxel + Nivolumab

EXPERIMENTAL

ADT (androgen deprivation therapy) plus DOCETAXEL plus NIVOLUMAB

Drug: Nivolumab 10 MG/ML; Drug: Docetaxel; Drug: ADT (androgen deprivation therapy)

ADT + Ipilimumab / Docetaxel + Nivolumab

EXPERIMENTAL

ADT (androgen deprivation therapy) plus IPILIMUMAB alternating with DOCETAXEL and followed by NIVOLUMAB

Drug: Ipilimumab 5 MG/ML; Drug: Nivolumab 10 MG/ML; Drug: Docetaxel; Drug: ADT (androgen deprivation therapy)

Interventions

Ipilimumab 5 MG/ML DRUG

Ipilimumab will be administered on day 1 of each cycle every 3 weeks. In arm 3, ipilimumab should be started at least 2 weeks but no later than 120 days after surgical castration or the first dose of LHRH analogue. Patients should receive 2 doses of ipilimumab (6 weeks). It will be followed, 3 weeks later, by 3 cycles of docetaxel and by 2 additional doses of ipilimumab and 3 more cycles of docetaxel. Four weeks later, Nivolumab will be administered on day 1 every 2 weeks until a maximum of 24 doses (48 weeks)

Also known as: YERVOY

ADT + Ipilimumab / Docetaxel + Nivolumab

Nivolumab 10 MG/ML DRUG

Nivolumab will be administered every 2 weeks, until clinical progression or a maximum of 24 doses. Nivolumab should be started 4 weeks after the last dose of docetaxel, providing all the adverse effects have recovered, as if a new cycle of docetaxel were to be administered

Also known as: Opdivo

ADT + Docetaxel + Nivolumab; ADT + Ipilimumab / Docetaxel + Nivolumab

Docetaxel DRUG

Docetaxel should be given on day 1 every 21 days, for up to 6 cycles (1 cycle = 21 days). Docetaxel should be started within 7 working days from the date of randomization in the arm 1 and 2. In arm 3, docetaxel will be given 3 weeks after the last dose of the previous treatment, providing all the side effects are grade ≤1.

ADT + Docetaxel; ADT + Docetaxel + Nivolumab; ADT + Ipilimumab / Docetaxel + Nivolumab

ADT (androgen deprivation therapy) DRUG

Androgen deprivation therapy per the standard of care

ADT + Docetaxel; ADT + Docetaxel + Nivolumab; ADT + Ipilimumab / Docetaxel + Nivolumab

Eligibility Criteria

• Age: 18 Years+
• Gender Eligibility Details: Condition is exclusive of males
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients must be at least 18 years of age
• Signed and dated written informed consent, obtained before the performance of any protocol-related procedure.
• Histological or cytological diagnosis of prostate cancer with an elevated PSA level and radiologic evidence of metastatic disease.
• ECOG performance-status score of 0, 1, or 2. Patients with a score of 2 are eligible if the decrement in functioning was due to prostate cancer.
• Metastatic disease that has spread beyond the prostate or relapsed after local therapy, documented by body CT scan and/or bone scan, according to PCWG 3 criteria, with high volume according to criteria used in the CHAARTED study.
• Radiological and scintigraphic studies to identify initial evaluable disease should be done as follows:
• If ADT has not been initiated, CT scans and bone scan must be obtained within 6 weeks prior to the start of ADT.
• If all required imaging had not been completed prior to starting ADT, any additional scan must be obtained after starting androgen deprivation but prior to randomization and the initiation of docetaxel (It is assumed that the scans of patients with high volume disease would not normalize in less than 120 days to the point that a patient would go from "high volume" to "low volume").
• Measurable or evaluable disease according to the PWGC 3.
• Patients who started ADT for metastatic disease are eligible if ADT commenced within 120 days before randomization, they have not started docetaxel chemotherapy yet, and there was no evidence of clinical, radiological or biochemical progression after ADT.
• Patients receiving ADT in the adjuvant and/or neoadjuvant setting for less than 30 months of therapy, AND the effect of the last depot injection had expired at least 12 months prior to documentation of metastatic disease, AND
• They had no evidence of disease (PSA \< 0.2 ng/dL) after prostatectomy plus hormonal therapy, or
• PSA was \< 0.5 ng/dL after completing radiation therapy plus adjuvant or neoadjuvant hormonal therapy, and had not doubled above nadir in at least 12 months.
• Patients must have adequate organ function within 4 weeks prior to randomization and evidenced by:
• Absolute Neutrophil Count \> 1500/mm 3

You may not qualify if:

• Patients are not eligible if the PSA has risen from its lowest point, between the beginning of androgen deprivation therapy and the date of randomization, and met criteria for progression as defined in the protocol.
• Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, PROSTVAC, Sipuleucel-T or any previous immunotherapy or vaccines for cancer.
• Prior chemotherapy in the adjuvant or neoadjuvant setting.
• Unable to receive docetaxel at full doses at investigator criteria.
• Peripheral neuropathy grade \> 1.
• All toxicities attributed to prior anti-cancer therapy other than neuropathy, alopecia or fatigue must have resolved to Grade 1 (NCI CTCAE version 4) or baseline before administration of study drug. Subjects with toxicities attributed to prior surgery or radiotherapy, which are not expected to resolve and result in long-term lasting sequelae, are permitted to enrol.
• History of hypersensitivity reaction to Docetaxel®, other drugs formulated with polysorbate 80, or monoclonal antibodies.
• Prior hormone therapy or immunotherapy in the metastatic setting.
• Prior palliative radiation therapy within 30 days of starting docetaxel.
• Known acute or chronic HIV, Hepatitis B, or Hepatitis C. Past Hepatitis B infection with no signs of activity later, are allowed
• Active brain metastases or leptomeningeal metastases, except if they have been treated and there is a magnetic resonance imaging (or CT scan if MRI were contraindicated) showing no evidence of progression for at least 4 weeks after the treatment
• Subjects with a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days previous to randomization. Inhaled or topical steroids and adrenal replacement doses \> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
• Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are allowed.
• Active cardiac disease defined as active angina, symptomatic congestive heart failure, or myocardial infarction within the previous six months
• History of malignancy in the past 5 years except for basal cell and squamous cell carcinoma of the skin and non-muscle-invasive bladder cancer. Other more malignancies considered to have a low potential to progress may be enrolled if approved by study chair.

Sponsors & Collaborators

• Spanish Oncology Genito-Urinary Group: lead
• Syntax for Science, S.L: collaborator
• Bristol-Myers Squibb: collaborator

Study Sites (30)

Hospital Son Llatzer

Palma de Mallorca, Balearic Islands, 07198, Spain

Location

Hestia Duran I Reynals

L'Hospitalet de Llobregat, Barcelona, 08908, Spain

Location

Hospital Sant Joan de Deu (Althaia Manresa)

Manresa, Barcelona, 08242, Spain

Location

Hospital de Sabadell

Sabadell, Barcelona, 08208, Spain

Location

Hospital General, Materno E Infantil Reina

Córdoba, Cordoba, 14004, Spain

Location

Hospital Universitario Puerta de Hierro Majadahonda

Majadahonda, Madrid, 28222, Spain

Location

Hospital Universitario Infanta Sofía

San Sebastián de los Reyes, Madrid, 28072, Spain

Location

Complejo Hospitalario de Navarra

Pamplona, Navarre, 31008, Spain

Location

Hospital Universitario Central de Asturias

Oviedo, Principality of Asturias, 33011, Spain

Location

Hospital Arnau de Vilanova

Valencia, Valenci, 46015, Spain

Location

Hospital de Basurto

Bilbao, Vizcaya, 48013, Spain

Location

Hospital Del Mar

Barcelona, 08003, Spain

Location

Hospital Universitari Vall D'Hebron

Barcelona, 08035, Spain

Location

Hospital Clínic de Barcelona

Barcelona, 08036, Spain

Location

Hospital Universitario de Burgos

Burgos, 09006, Spain

Location

Hospital San Pedro de Alcántara

Cáceres, 10003, Spain

Location

Hospital General de Ciudad Real

Ciudad Real, 13005, Spain

Location

Hospital Universitari de Girona Dr. Josep Trueta

Girona, 17007, Spain

Location

Hospital Universitario Lucus Augusti

Lugo, 27003, Spain

Location

Hospital General Universitario Gregorio Marañón

Madrid, 28007, Spain

Location

Hospital Ramón Y Cajal

Madrid, 28013, Spain

Location

Hospital Clínico San Carlos

Madrid, 28040, Spain

Location

Hospital Universitario 12 de Octubre

Madrid, 28041, Spain

Location

Hospital Virgen Del Rocío

Seville, 41013, Spain

Location

Hospital Nuestra Señora de Valme

Seville, 41014, Spain

Location

Hospital Virgen Macarena

Seville, 41071, Spain

Location

Hospital Virgen de La Salud

Toledo, 45004, Spain

Location

Fundación Instituto Valenciano de Oncología

Valencia, 46009, Spain

Location

Consorcio Hospital General Universitario de Valencia

Valencia, 46014, Spain

Location

Hospital Universitario Alvaro Cunqueiro

Vigo, 36312, Spain

Location

MeSH Terms

Conditions

Prostatic Neoplasms

Interventions

Ipilimumab; Nivolumab; Docetaxel; Androgen Antagonists

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins; Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Diterpenes; Terpenes; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Physiological Effects of Drugs; Pharmacologic Actions; Chemical Actions and Uses

Study Officials

• Jose Ángel Arranz Arija, MD, PhD

  Physician - Investigator

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Multi-arm multi-stage (MAMS), multi-centre randomised controlled trial with 3 arms (2 experimental arms and a control arm) and 4 stages (three intermediate and a final stage). In all 3 intermediate stages of the trial, each experimental arm is compared in a pairwise manner with the control arm using an "intermediate" outcome measure. Experimental arms that do not reach a predefined critical value are discontinued. In the final stage, the remaining(s) arm(s) will be compared with the control arm in terms of overall survival (definitive outcome). The 3 arms included in this trial are the Control arm (ARM 1): ADT plus 6 cycles of DOCETAXEL and 2 experimental arms: ADT plus DOCETAXEL plus NIVOLUMAB (ARM 2) and ADT plus IPILIMUMAB alternating with DOCETAXEL and with NIVOLUMAB (ARM 3). Other experimental arms could be included later.

Study Record Dates

• First Submitted: March 13, 2019
• First Posted: March 18, 2019
• Study Start: February 11, 2019
• Primary Completion: July 31, 2023
• Study Completion: December 31, 2024
• Last Updated: October 26, 2022

Record last verified: 2022-10

Locations

ES (30)